Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

August 14, 2014 updated by: GlaxoSmithKline

A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer

This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radiographic evidence of disease.

Study Overview

Status

Completed

Conditions

Neoplasms, Breast

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

3166

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Argentina
- - Ciudad Autónoma de Buenos Aires, Argentina, C1417DTN
    - GSK Investigational Site
  - Quilmes, Argentina, 1878
    - GSK Investigational Site
  - San Miguel de Tucumán, Argentina, T4000IAK
    - GSK Investigational Site
  - Santa Fe, Argentina, 3000
    - GSK Investigational Site
- Buenos Aires
  - Capital Federal, Buenos Aires, Argentina, C1405CUB
    - GSK Investigational Site
  - Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1405BCH
    - GSK Investigational Site
  - Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1185AAT
    - GSK Investigational Site
- Córdova
  - Córdoba, Córdova, Argentina, X5006HBF
    - GSK Investigational Site
- Neuquén
  - Neuquen, Neuquén, Argentina, Q8300HDH
    - GSK Investigational Site
- Santa Fe
  - Rosario, Santa Fe, Argentina, S2000KZE
    - GSK Investigational Site
Australia
- New South Wales
  - Campbelltown, New South Wales, Australia, 2560
    - GSK Investigational Site
  - Darlinghurst, New South Wales, Australia, 2010
    - GSK Investigational Site
  - Kogarah, New South Wales, Australia, 2217
    - GSK Investigational Site
  - Liverpool, New South Wales, Australia, 2170
    - GSK Investigational Site
  - North Sydney, New South Wales, Australia, 2060
    - GSK Investigational Site
- Queensland
  - Douglas, Queensland, Australia, 4814
    - GSK Investigational Site
  - Herston, Queensland, Australia, 4029
    - GSK Investigational Site
  - Redcliffe, Queensland, Australia, 4020
    - GSK Investigational Site
  - South Brisbane, Queensland, Australia, 4101
    - GSK Investigational Site
- South Australia
  - Bedford Park, South Australia, Australia, 5042
    - GSK Investigational Site
  - Elizabeth Vale, South Australia, Australia, 5112
    - GSK Investigational Site
  - Woodville, South Australia, Australia, 5011
    - GSK Investigational Site
- Victoria
  - Box Hill, Victoria, Australia, 3128
    - GSK Investigational Site
  - East Melbourne, Victoria, Australia, 3002
    - GSK Investigational Site
  - Fitzroy, Victoria, Australia, 3065
    - GSK Investigational Site
  - Footscray, Victoria, Australia, 3011
    - GSK Investigational Site
  - Heidelberg, Victoria, Australia, 3084
    - GSK Investigational Site
  - Parkville, Victoria, Australia, 3050
    - GSK Investigational Site
  - Ringwood East, Victoria, Australia, 3135
    - GSK Investigational Site
  - Wodonga, Victoria, Australia, 3690
    - GSK Investigational Site
- Western Australia
  - Nedlands, Western Australia, Australia, 6009
    - GSK Investigational Site
  - Perth, Western Australia, Australia, 6000
    - GSK Investigational Site
Belgium
- - Bruxelles, Belgium, 1000
    - GSK Investigational Site
Brazil
- - Rio de Janeiro, Brazil, 21941-913
    - GSK Investigational Site
  - São Paulo, Brazil, 03102-002
    - GSK Investigational Site
- Minas Gerais
  - Belo Horizonte, Minas Gerais, Brazil, 30.140-001
    - GSK Investigational Site
- Rio Grande Do Sul
  - Porto Alegre, Rio Grande Do Sul, Brazil, 90020-090
    - GSK Investigational Site
  - Porto Alegre, Rio Grande Do Sul, Brazil, 90610 000
    - GSK Investigational Site
- São Paulo
  - Santo Andre, São Paulo, Brazil, 09060-670
    - GSK Investigational Site
Canada
- - Quebec, Canada, G1S 4L8
    - GSK Investigational Site
- Newfoundland and Labrador
  - St. John's, Newfoundland and Labrador, Canada, A1B 3V6
    - GSK Investigational Site
- Nova Scotia
  - Halifax, Nova Scotia, Canada, B3H 1V7
    - GSK Investigational Site
- Ontario
  - Barrie, Ontario, Canada, L4M 6M2
    - GSK Investigational Site
  - Brampton, Ontario, Canada, L6W 2Z8
    - GSK Investigational Site
  - Kingston, Ontario, Canada, K7L 5P9
    - GSK Investigational Site
  - London, Ontario, Canada, N6A 4L6
    - GSK Investigational Site
  - Mississauga, Ontario, Canada, L5M 2N1
    - GSK Investigational Site
  - Oshawa, Ontario, Canada, L1G 2B9
    - GSK Investigational Site
  - Ottawa, Ontario, Canada, K1H 8L6
    - GSK Investigational Site
  - Toronto, Ontario, Canada, M4N 3M5
    - GSK Investigational Site
  - Toronto, Ontario, Canada, M5B 1W8
    - GSK Investigational Site
  - Toronto, Ontario, Canada, M4C 3E7
    - GSK Investigational Site
  - Toronto, Ontario, Canada, M6R 1B5
    - GSK Investigational Site
- Quebec
  - Greenfield Park, Quebec, Canada, J4V 2H1
    - GSK Investigational Site
  - Montreal, Quebec, Canada, H3T 1E2
    - GSK Investigational Site
- Saskatchewan
  - Saskatoon, Saskatchewan, Canada, S7N 4H4
    - GSK Investigational Site
Chile
- Región Metro De Santiago
  - Santiago, Región Metro De Santiago, Chile, 7500921
    - GSK Investigational Site
  - Santiago, Región Metro De Santiago, Chile, 7591046
    - GSK Investigational Site
  - Santiago, Región Metro De Santiago, Chile, 750 1088
    - GSK Investigational Site
- Valparaíso
  - Viña del Mar, Valparaíso, Chile, 254-0364
    - GSK Investigational Site
China
- - Beijing, China, 100021
    - GSK Investigational Site
  - Beijing, China, 100071
    - GSK Investigational Site
  - Beijing, China, 100036
    - GSK Investigational Site
  - Shanghai, China, 200032
    - GSK Investigational Site
  - Tianjin, China, 300060
    - GSK Investigational Site
- Guangdong
  - Guangzhou, Guangdong, China, 510060
    - GSK Investigational Site
- Hubei
  - Wuhan, Hubei, China, 430030
    - GSK Investigational Site
- Shandong
  - Jinan, Shandong, China, 250117
    - GSK Investigational Site
Croatia
- - Osijek, Croatia, 31000
    - GSK Investigational Site
  - Pula, Croatia, 52 100
    - GSK Investigational Site
  - Rijeka, Croatia, 51000
    - GSK Investigational Site
  - Split, Croatia, 21000
    - GSK Investigational Site
  - Zagreb, Croatia, 10 000
    - GSK Investigational Site
Czech Republic
- - Brno, Czech Republic, 656 53
    - GSK Investigational Site
  - Prague 2, Czech Republic, 121 00
    - GSK Investigational Site
  - Praha 8, Czech Republic, 180 00
    - GSK Investigational Site
Denmark
- - Aalborg, Denmark, 9100
    - GSK Investigational Site
  - Copenhagen, Denmark, DK-2100
    - GSK Investigational Site
  - Esbjerg, Denmark, 6700
    - GSK Investigational Site
  - Herlev, Denmark, DK-2730
    - GSK Investigational Site
  - Naestved, Denmark, 4700
    - GSK Investigational Site
  - Odense, Denmark, 5000
    - GSK Investigational Site
  - Roskilde, Denmark, 4000
    - GSK Investigational Site
  - Vejle, Denmark, 7100
    - GSK Investigational Site
France
- - Angers, France, 49933
    - GSK Investigational Site
  - Besançon, France, 25030
    - GSK Investigational Site
  - Bordeaux, France, 33000
    - GSK Investigational Site
  - Caen Cedex 05, France, 14076
    - GSK Investigational Site
  - Clermont Ferrand, France, 63000
    - GSK Investigational Site
  - Colmar Cedex, France, 68024
    - GSK Investigational Site
  - Dijon Cedex, France, 21079
    - GSK Investigational Site
  - Lille, France, 59000
    - GSK Investigational Site
  - Lille cedex, France, 59020
    - GSK Investigational Site
  - Lyon, France, 69008
    - GSK Investigational Site
  - Lyon Cedex 08, France, 69373
    - GSK Investigational Site
  - Marseille Cedex 09, France, 13273
    - GSK Investigational Site
  - Montbeliard, France, 25200
    - GSK Investigational Site
  - Montpellier Cedex 5, France, 34298
    - GSK Investigational Site
  - Nantes cedex, France, 44202
    - GSK Investigational Site
  - Nice Cedex 2, France, 06189
    - GSK Investigational Site
  - Paris Cedex 15, France, 75908
    - GSK Investigational Site
  - Reims, France, 51100
    - GSK Investigational Site
  - Rennes, France, 35042
    - GSK Investigational Site
  - Saint Grégoire, France, 35760
    - GSK Investigational Site
  - Saint-Cloud, France, 92210
    - GSK Investigational Site
  - Saint-Herblain, France, 44805
    - GSK Investigational Site
  - Strasbourg, France, 67000
    - GSK Investigational Site
  - Toulouse Cedex 3, France, 31076
    - GSK Investigational Site
  - Toulouse Cedex 9, France, 31059
    - GSK Investigational Site
  - Tourcoing, France, 59200
    - GSK Investigational Site
  - Vandoeuvre-Les-Nancy, France, 54511
    - GSK Investigational Site
  - Villejuif, France, 94804
    - GSK Investigational Site
  - Villejuif Cedex, France, 94805
    - GSK Investigational Site
Germany
- - Berlin, Germany, 10367
    - GSK Investigational Site
  - Berlin, Germany, 10117
    - GSK Investigational Site
  - Berlin, Germany, 13125
    - GSK Investigational Site
  - Berlin, Germany, 14169
    - GSK Investigational Site
  - Berlin, Germany, 14197
    - GSK Investigational Site
  - Berlin, Germany, 13156
    - GSK Investigational Site
  - Berlin, Germany, 12683
    - GSK Investigational Site
  - Bremen, Germany, 28177
    - GSK Investigational Site
  - Bremen, Germany, 28209
    - GSK Investigational Site
  - Hamburg, Germany, 20246
    - GSK Investigational Site
  - Hamburg, Germany, 22457
    - GSK Investigational Site
  - Hamburg, Germany, 22081
    - GSK Investigational Site
- Baden-Wuerttemberg
  - Freiburg, Baden-Wuerttemberg, Germany, 79106
    - GSK Investigational Site
  - Heidelberg, Baden-Wuerttemberg, Germany, 69115
    - GSK Investigational Site
  - Konstanz, Baden-Wuerttemberg, Germany, 78464
    - GSK Investigational Site
  - Mannheim, Baden-Wuerttemberg, Germany, 68161
    - GSK Investigational Site
  - Mayen, Baden-Wuerttemberg, Germany, 56727
    - GSK Investigational Site
  - Mutlangen, Baden-Wuerttemberg, Germany, 73557
    - GSK Investigational Site
  - Rheinfelden, Baden-Wuerttemberg, Germany, 79618
    - GSK Investigational Site
  - Schwetzingen, Baden-Wuerttemberg, Germany, 68723
    - GSK Investigational Site
  - Singen, Baden-Wuerttemberg, Germany, 78224
    - GSK Investigational Site
  - Stuttgart, Baden-Wuerttemberg, Germany, 70376
    - GSK Investigational Site
  - Stuttgart, Baden-Wuerttemberg, Germany, 70190
    - GSK Investigational Site
  - Tuebingen, Baden-Wuerttemberg, Germany, 72076
    - GSK Investigational Site
  - Ulm, Baden-Wuerttemberg, Germany, 89075
    - GSK Investigational Site
- Bayern
  - Amberg, Bayern, Germany, 92224
    - GSK Investigational Site
  - Aschaffenburg, Bayern, Germany, 63739
    - GSK Investigational Site
  - Bayreuth, Bayern, Germany, 95445
    - GSK Investigational Site
  - Deggendorf, Bayern, Germany, 94469
    - GSK Investigational Site
  - Ebersberg, Bayern, Germany, 85560
    - GSK Investigational Site
  - Eggenfelden, Bayern, Germany, 84307
    - GSK Investigational Site
  - Erlangen, Bayern, Germany, 91054
    - GSK Investigational Site
  - Fuerth, Bayern, Germany, 90766
    - GSK Investigational Site
  - Kempten, Bayern, Germany, 87439
    - GSK Investigational Site
  - Krumbach, Bayern, Germany, 86381
    - GSK Investigational Site
  - Marktredwitz, Bayern, Germany, 95615
    - GSK Investigational Site
  - Memmingen, Bayern, Germany, 87700
    - GSK Investigational Site
  - Muenchen, Bayern, Germany, 80335
    - GSK Investigational Site
  - Muenchen, Bayern, Germany, 81377
    - GSK Investigational Site
  - Muenchen, Bayern, Germany, 80331
    - GSK Investigational Site
  - Muenchen, Bayern, Germany, 80337
    - GSK Investigational Site
  - Muenchen, Bayern, Germany, 80637
    - GSK Investigational Site
  - Rehling, Bayern, Germany, 86508
    - GSK Investigational Site
  - Rosenheim, Bayern, Germany, 83022
    - GSK Investigational Site
  - Roth, Bayern, Germany, 91154
    - GSK Investigational Site
  - Schwandorf, Bayern, Germany, 92421
    - GSK Investigational Site
  - Weiden, Bayern, Germany, 92637
    - GSK Investigational Site
- Brandenburg
  - Cottbus, Brandenburg, Germany, 03046
    - GSK Investigational Site
  - Fuerstenwalde, Brandenburg, Germany, 15517
    - GSK Investigational Site
- Hessen
  - Frankfurt, Hessen, Germany, 60596
    - GSK Investigational Site
  - Frankfurt, Hessen, Germany, 60389
    - GSK Investigational Site
  - Frankfurt, Hessen, Germany, 65929
    - GSK Investigational Site
  - Frankfurt am Main, Hessen, Germany, 60590
    - GSK Investigational Site
  - Kassel, Hessen, Germany, 34117
    - GSK Investigational Site
  - Kassel, Hessen, Germany, 34131
    - GSK Investigational Site
  - Wiesbaden, Hessen, Germany, 65191
    - GSK Investigational Site
- Mecklenburg-Vorpommern
  - Guestrow, Mecklenburg-Vorpommern, Germany, 18273
    - GSK Investigational Site
- Niedersachsen
  - Goslar, Niedersachsen, Germany, 38642
    - GSK Investigational Site
  - Hannover, Niedersachsen, Germany, 30625
    - GSK Investigational Site
  - Hildesheim, Niedersachsen, Germany, 31134
    - GSK Investigational Site
  - Salzgitter, Niedersachsen, Germany, 38226
    - GSK Investigational Site
- Nordrhein-Westfalen
  - Bochum, Nordrhein-Westfalen, Germany, 44799
    - GSK Investigational Site
  - Bonn, Nordrhein-Westfalen, Germany, 53113
    - GSK Investigational Site
  - Duesseldorf, Nordrhein-Westfalen, Germany, 40235
    - GSK Investigational Site
  - Duisburg, Nordrhein-Westfalen, Germany, 47051
    - GSK Investigational Site
  - Duisburg, Nordrhein-Westfalen, Germany, 47166
    - GSK Investigational Site
  - Essen, Nordrhein-Westfalen, Germany, 45130
    - GSK Investigational Site
  - Herne, Nordrhein-Westfalen, Germany, 44623
    - GSK Investigational Site
  - Hilden, Nordrhein-Westfalen, Germany, 40724
    - GSK Investigational Site
  - Koeln, Nordrhein-Westfalen, Germany, 50937
    - GSK Investigational Site
  - Koeln, Nordrhein-Westfalen, Germany, 50677
    - GSK Investigational Site
  - Muelheim, Nordrhein-Westfalen, Germany, 45473
    - GSK Investigational Site
  - Porta Westfalica, Nordrhein-Westfalen, Germany, 32457
    - GSK Investigational Site
  - Recklinghausen, Nordrhein-Westfalen, Germany, 45657
    - GSK Investigational Site
  - Troisdorf, Nordrhein-Westfalen, Germany, 53840
    - GSK Investigational Site
  - Velbert, Nordrhein-Westfalen, Germany, 42551
    - GSK Investigational Site
  - Witten, Nordrhein-Westfalen, Germany, 58452
    - GSK Investigational Site
- Rheinland-Pfalz
  - Koblenz, Rheinland-Pfalz, Germany, 56068
    - GSK Investigational Site
  - Mainz, Rheinland-Pfalz, Germany, 55131
    - GSK Investigational Site
- Saarland
  - Homburg/Saar, Saarland, Germany, 66421
    - GSK Investigational Site
  - Neunkirchen, Saarland, Germany, 66538
    - GSK Investigational Site
  - Saarbruecken, Saarland, Germany, 66113
    - GSK Investigational Site
- Sachsen
  - Chemnitz, Sachsen, Germany, 09116
    - GSK Investigational Site
  - Dresden, Sachsen, Germany, 01307
    - GSK Investigational Site
  - Kauschwitz, Sachsen, Germany, 08525
    - GSK Investigational Site
  - Neustadt, Sachsen, Germany, 01844
    - GSK Investigational Site
  - Spremberg, Sachsen, Germany, 03130
    - GSK Investigational Site
  - Zittau, Sachsen, Germany, 02763
    - GSK Investigational Site
  - Zwickau, Sachsen, Germany, 08060
    - GSK Investigational Site
- Sachsen-Anhalt
  - Blankenburg, Sachsen-Anhalt, Germany, 38889
    - GSK Investigational Site
  - Halle, Sachsen-Anhalt, Germany, 06120
    - GSK Investigational Site
  - Magdeburg, Sachsen-Anhalt, Germany, 39104
    - GSK Investigational Site
  - Magdeburg, Sachsen-Anhalt, Germany, 39108
    - GSK Investigational Site
  - Stendal, Sachsen-Anhalt, Germany, 39576
    - GSK Investigational Site
- Schleswig-Holstein
  - Kiel, Schleswig-Holstein, Germany, 24103
    - GSK Investigational Site
  - Luebeck, Schleswig-Holstein, Germany, 23538
    - GSK Investigational Site
- Thueringen
  - Eisenach, Thueringen, Germany, 99817
    - GSK Investigational Site
  - Jena, Thueringen, Germany, 07743
    - GSK Investigational Site
Greece
- - Athens, Greece, 115 27
    - GSK Investigational Site
  - Athens, Greece, 11527
    - GSK Investigational Site
  - Athens, Greece, 185 37
    - GSK Investigational Site
  - Chania, Greece, 73100
    - GSK Investigational Site
  - Heraklion, Crete, Greece, 71110
    - GSK Investigational Site
Hong Kong
- - Hong Kong, Hong Kong
    - GSK Investigational Site
  - Shatin, Hong Kong
    - GSK Investigational Site
  - Wanchai, Hong Kong
    - GSK Investigational Site
Hungary
- - Budapest, Hungary
    - GSK Investigational Site
  - Budapest, Hungary, 1076
    - GSK Investigational Site
  - Győr, Hungary, 9023
    - GSK Investigational Site
  - Kaposvár, Hungary, 7400
    - GSK Investigational Site
  - Kistarcsa, Hungary, 2143
    - GSK Investigational Site
  - Pécs, Hungary, 7624
    - GSK Investigational Site
  - Szeged, Hungary, 6720
    - GSK Investigational Site
India
- - Chennai, India, 600035
    - GSK Investigational Site
  - Hyderabad, India, 500082
    - GSK Investigational Site
  - Jaipur, India, 302013
    - GSK Investigational Site
  - Mumbai, India, 400012
    - GSK Investigational Site
  - New Delhi, India
    - GSK Investigational Site
  - Pune, India, 411001
    - GSK Investigational Site
Israel
- - Ashkelon, Israel, 78278
    - GSK Investigational Site
  - Haifa, Israel, 34362
    - GSK Investigational Site
  - Jerusalem, Israel, 91120
    - GSK Investigational Site
  - Kfar Saba, Israel, 44281
    - GSK Investigational Site
  - Ramat Gan, Israel, 52621
    - GSK Investigational Site
  - Rehovot, Israel, 76100
    - GSK Investigational Site
  - Tel Aviv, Israel, 64239
    - GSK Investigational Site
Italy
- Campania
  - Avellino, Campania, Italy, 83100
    - GSK Investigational Site
- Emilia-Romagna
  - Piacenza, Emilia-Romagna, Italy, 29100
    - GSK Investigational Site
- Liguria
  - Genova, Liguria, Italy, 16132
    - GSK Investigational Site
- Sardegna
  - Sassari, Sardegna, Italy, 07100
    - GSK Investigational Site
- Umbria
  - Perugia, Umbria, Italy, 06132
    - GSK Investigational Site
- Veneto
  - Negrar (Verona), Veneto, Italy, 37024
    - GSK Investigational Site
Korea, Republic of
- - Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769
    - GSK Investigational Site
  - Seoul, Korea, Republic of, 110-744
    - GSK Investigational Site
  - Seoul, Korea, Republic of, 135-710
    - GSK Investigational Site
  - songpa-gu, Seoul, Korea, Republic of, 138-736
    - GSK Investigational Site
Latvia
- - Liepaja, Latvia, LV3401
    - GSK Investigational Site
  - Riga, Latvia, LV 1002
    - GSK Investigational Site
  - Riga, Latvia, LV 1079
    - GSK Investigational Site
Lithuania
- - Kaunas, Lithuania, LT-50009
    - GSK Investigational Site
  - Klaipeda, Lithuania, LT-92228
    - GSK Investigational Site
  - Vilnius, Lithuania, LT-08660
    - GSK Investigational Site
Mexico
- - Chihuahua, Mexico, 31000
    - GSK Investigational Site
  - DF., Mexico, 01120
    - GSK Investigational Site
  - Mexico City, Mexico, CP 14080
    - GSK Investigational Site
  - México D.F., Mexico, 11000
    - GSK Investigational Site
- Yucatán
  - Mérida, Yucatán, Mexico, 97500
    - GSK Investigational Site
New Zealand
- - Auckland, New Zealand, 1023
    - GSK Investigational Site
  - Christchurch, New Zealand, 8001
    - GSK Investigational Site
  - Hamilton, New Zealand, 2001
    - GSK Investigational Site
Peru
- - Lima, Peru, Lima 11
    - GSK Investigational Site
  - Lima, Peru, Lima 34
    - GSK Investigational Site
  - Lima, Peru, Lima 13
    - GSK Investigational Site
Philippines
- - Baguio City, Benguet, Philippines, 2600
    - GSK Investigational Site
  - Cebu, Philippines, 6000
    - GSK Investigational Site
  - Pasig City, Philippines, 1600
    - GSK Investigational Site
  - Quezon City, Philippines, 1101
    - GSK Investigational Site
Poland
- - Bydgoszcz, Poland, 85-792
    - GSK Investigational Site
  - Krakow, Poland, 31-115
    - GSK Investigational Site
  - Olsztyn, Poland, 10-228
    - GSK Investigational Site
  - Olsztyn, Poland, 10-226
    - GSK Investigational Site
  - Torun, Poland, 87-100
    - GSK Investigational Site
  - Warszawa, Poland, 00-909
    - GSK Investigational Site
Russian Federation
- - Moscow, Russian Federation, 117997
    - GSK Investigational Site
  - Moscow, Russian Federation, 115 478
    - GSK Investigational Site
  - Moscow, Russian Federation, 129301
    - GSK Investigational Site
  - Ryazan, Russian Federation, 390011
    - GSK Investigational Site
  - St. Petersburg, Russian Federation, 197022
    - GSK Investigational Site
  - St. Petersburg, Russian Federation, 197758
    - GSK Investigational Site
  - Yaroslavl, Russian Federation, 150054
    - GSK Investigational Site
Slovakia
- - Banska Bystrica, Slovakia, 975 17
    - GSK Investigational Site
  - Bardejov, Slovakia, 085 01
    - GSK Investigational Site
  - Bratislava, Slovakia, 833 10
    - GSK Investigational Site
  - Nitra, Slovakia, 950 01
    - GSK Investigational Site
South Africa
- - Athlone Park, Amanzimtoti, South Africa, 4126
    - GSK Investigational Site
  - Groenkloof, South Africa, 0181
    - GSK Investigational Site
  - Kraaifontein, South Africa, 7570
    - GSK Investigational Site
  - Overport, South Africa, 4091
    - GSK Investigational Site
  - Parktown, South Africa, 2193
    - GSK Investigational Site
  - Port Elizabeth, South Africa, 6045
    - GSK Investigational Site
  - Sandton, South Africa, 2199
    - GSK Investigational Site
  - Saxonwold, Johannesburg, South Africa, 2196
    - GSK Investigational Site
- Western Province
  - Tygerberg, Western Province, South Africa, 7505
    - GSK Investigational Site
Spain
- - Alcorcon, Spain, 28922
    - GSK Investigational Site
  - Barcelona, Spain, 08035
    - GSK Investigational Site
  - Barcelona, Spain, 08003
    - GSK Investigational Site
  - Cáceres, Spain, 10003
    - GSK Investigational Site
  - Girona, Spain, 17007
    - GSK Investigational Site
  - Jaén, Spain, 23007
    - GSK Investigational Site
  - Lerida, Spain, 25198
    - GSK Investigational Site
  - Llobregat, Spain, 08907
    - GSK Investigational Site
  - Madrid, Spain, 28040
    - GSK Investigational Site
  - Madrid, Spain, 28034
    - GSK Investigational Site
  - Mataró, Spain, 08304
    - GSK Investigational Site
  - Orense, Spain, 32005
    - GSK Investigational Site
  - Palma de Mallorca, Spain, 07010
    - GSK Investigational Site
  - Palma de Mallorca, Spain, 07198
    - GSK Investigational Site
  - Santa Cruz de Tenerife, Spain, 38320
    - GSK Investigational Site
  - Santander, Spain, 39008
    - GSK Investigational Site
  - Santiago de Compostela, Spain, 15706
    - GSK Investigational Site
  - Valencia, Spain, 46010
    - GSK Investigational Site
  - Zaragoza, Spain, 50009
    - GSK Investigational Site
Ukraine
- - Dnepropetrovsk, Ukraine, 49102
    - GSK Investigational Site
  - Kyiv, Ukraine, 03115
    - GSK Investigational Site
  - Lvov, Ukraine, 79031
    - GSK Investigational Site
  - Uzhgorod, Ukraine, 88017
    - GSK Investigational Site
United Kingdom
- - Bournemouth, United Kingdom, BH7 7DW
    - GSK Investigational Site
  - Edgbaston, Birmingham, United Kingdom, B15 2TH
    - GSK Investigational Site
  - Glasgow, United Kingdom, G12 OYN
    - GSK Investigational Site
  - Lindley, United Kingdom, HD3 3EA
    - GSK Investigational Site
  - London, United Kingdom, SE1 9RT
    - GSK Investigational Site
  - London, United Kingdom, NW1 2PG
    - GSK Investigational Site
  - London, United Kingdom, NW3 2QG
    - GSK Investigational Site
  - London, United Kingdom, SW3 6JJ
    - GSK Investigational Site
  - Maidstone, United Kingdom, ME16 9QQ
    - GSK Investigational Site
  - Manchester, United Kingdom, M23 9LT
    - GSK Investigational Site
  - Newcastle upon Tyne, United Kingdom, NE7 7DN
    - GSK Investigational Site
  - Nottingham, United Kingdom, NG5 1PB
    - GSK Investigational Site
  - Sheffield, United Kingdom, S10 2SJ
    - GSK Investigational Site
  - Shrewsbury, United Kingdom, SY3 8XQ
    - GSK Investigational Site
- Essex
  - Chelmsford, Essex, United Kingdom, CM1 7ET
    - GSK Investigational Site
- Lancashire
  - Manchester, Lancashire, United Kingdom, M20 4BX
    - GSK Investigational Site
- Surrey
  - Sutton, Surrey, United Kingdom, SM2 5PT
    - GSK Investigational Site
United States
- Alabama
  - Tuscaloosa, Alabama, United States, 35406
    - GSK Investigational Site
- Arizona
  - Phoenix, Arizona, United States, 85012
    - GSK Investigational Site
  - Sedona, Arizona, United States, 86336
    - GSK Investigational Site
  - Tucson, Arizona, United States, 85715
    - GSK Investigational Site
- Arkansas
  - Fayetteville, Arkansas, United States, 72703
    - GSK Investigational Site
  - Jonesboro, Arkansas, United States, 72401
    - GSK Investigational Site
  - Little Rock, Arkansas, United States, 72205
    - GSK Investigational Site
- California
  - Anaheim, California, United States, 92801
    - GSK Investigational Site
  - Bakersfield, California, United States, 93309
    - GSK Investigational Site
  - Gilroy, California, United States, 95020
    - GSK Investigational Site
  - La Jolla, California, United States, 92037
    - GSK Investigational Site
  - La Verne, California, United States, 91750
    - GSK Investigational Site
  - Palm Springs, California, United States, 92262
    - GSK Investigational Site
  - Rancho Mirage, California, United States, 92270
    - GSK Investigational Site
- Colorado
  - Denver, Colorado, United States, 80220
    - GSK Investigational Site
- Connecticut
  - Fairfield, Connecticut, United States, 06824
    - GSK Investigational Site
  - Norwalk, Connecticut, United States, 06856
    - GSK Investigational Site
  - Torrington, Connecticut, United States, 06790
    - GSK Investigational Site
- District of Columbia
  - Washington, District of Columbia, United States, 20007
    - GSK Investigational Site
  - Washington, District of Columbia, United States, 20010
    - GSK Investigational Site
- Florida
  - Boca Raton, Florida, United States, 33428
    - GSK Investigational Site
  - Boynton Beach, Florida, United States, 33437
    - GSK Investigational Site
  - Gainesville, Florida, United States, 32605
    - GSK Investigational Site
  - New Port Richey, Florida, United States, 34655
    - GSK Investigational Site
  - Ocala, Florida, United States, 34474
    - GSK Investigational Site
  - Orlando, Florida, United States, 32806
    - GSK Investigational Site
  - Plantation, Florida, United States, 33324
    - GSK Investigational Site
  - Port St. Lucie, Florida, United States, 34952
    - GSK Investigational Site
- Georgia
  - Augusta, Georgia, United States, 30901
    - GSK Investigational Site
  - Marietta, Georgia, United States, 30060
    - GSK Investigational Site
- Illinois
  - Chicago, Illinois, United States, 60611
    - GSK Investigational Site
  - Chicago, Illinois, United States, 60611-2906
    - GSK Investigational Site
  - Joliet, Illinois, United States, 60435
    - GSK Investigational Site
  - Park Ridge, Illinois, United States, 60068
    - GSK Investigational Site
- Indiana
  - Indianapolis, Indiana, United States, 46219
    - GSK Investigational Site
- Iowa
  - Ames, Iowa, United States, 50010
    - GSK Investigational Site
  - Sioux City, Iowa, United States, 51101-1733
    - GSK Investigational Site
- Kansas
  - Wichita, Kansas, United States, 67214
    - GSK Investigational Site
- Kentucky
  - Louisville, Kentucky, United States, 40245
    - GSK Investigational Site
- Louisiana
  - Marrero, Louisiana, United States, 70072
    - GSK Investigational Site
- Maine
  - Scarborough, Maine, United States, 4074
    - GSK Investigational Site
- Maryland
  - Bethesda, Maryland, United States, 20817
    - GSK Investigational Site
- Massachusetts
  - Boston, Massachusetts, United States, 02114
    - GSK Investigational Site
  - Danvers, Massachusetts, United States, 01923
    - GSK Investigational Site
  - Newton, Massachusetts, United States, 02462
    - GSK Investigational Site
- Michigan
  - Kalamazoo, Michigan, United States, 49048
    - GSK Investigational Site
- Minnesota
  - Duluth, Minnesota, United States, 55805
    - GSK Investigational Site
  - Edina, Minnesota, United States, 55435
    - GSK Investigational Site
  - Minneapolis, Minnesota, United States, 55404
    - GSK Investigational Site
  - Robbinsdale, Minnesota, United States, 55422
    - GSK Investigational Site
- Missouri
  - Columbia, Missouri, United States, 65201
    - GSK Investigational Site
  - Kansas City, Missouri, United States, 64118
    - GSK Investigational Site
  - Saint Louis, Missouri, United States, 63109
    - GSK Investigational Site
  - St. Joseph, Missouri, United States, 64507
    - GSK Investigational Site
  - St. Louis, Missouri, United States, 63141
    - GSK Investigational Site
- New Hampshire
  - Hooksett, New Hampshire, United States, 03106
    - GSK Investigational Site
- New Jersey
  - Cherry Hill, New Jersey, United States, 08003
    - GSK Investigational Site
  - Morristown, New Jersey, United States, 07962
    - GSK Investigational Site
  - Paramus, New Jersey, United States, 07652
    - GSK Investigational Site
  - Sparta, New Jersey, United States, 07871
    - GSK Investigational Site
- New York
  - Albany, New York, United States, 12206
    - GSK Investigational Site
  - East Setauket, New York, United States, 11733
    - GSK Investigational Site
  - Mount Kisco, New York, United States, 10590
    - GSK Investigational Site
  - New York, New York, United States, 10016
    - GSK Investigational Site
  - New York, New York, United States, 10003
    - GSK Investigational Site
  - Rochester, New York, United States, 14623
    - GSK Investigational Site
- North Carolina
  - Charleston, North Carolina, United States, 29406
    - GSK Investigational Site
  - Gastonia, North Carolina, United States, 28054
    - GSK Investigational Site
  - Greensboro, North Carolina, United States, 27403
    - GSK Investigational Site
  - Hickory, North Carolina, United States, 28602
    - GSK Investigational Site
- Ohio
  - Cleveland, Ohio, United States, 44106
    - GSK Investigational Site
  - Cleveland, Ohio, United States, 44195
    - GSK Investigational Site
  - Columbus, Ohio, United States, 43215
    - GSK Investigational Site
  - Middletown, Ohio, United States, 45042
    - GSK Investigational Site
- Pennsylvania
  - Drexel Hill, Pennsylvania, United States, 19026
    - GSK Investigational Site
  - Philadelphia, Pennsylvania, United States, 19107
    - GSK Investigational Site
- South Carolina
  - Charleston, South Carolina, United States, 29414
    - GSK Investigational Site
- Tennessee
  - Chattanooga, Tennessee, United States, 37403
    - GSK Investigational Site
  - Germantown, Tennessee, United States, 38138
    - GSK Investigational Site
  - Memphis, Tennessee, United States, 38120
    - GSK Investigational Site
- Texas
  - Austin, Texas, United States, 78705
    - GSK Investigational Site
  - Austin, Texas, United States, 78759
    - GSK Investigational Site
  - Bedford, Texas, United States, 76022
    - GSK Investigational Site
  - Dallas, Texas, United States, 75246
    - GSK Investigational Site
  - Dallas, Texas, United States, 75230
    - GSK Investigational Site
  - Dallas, Texas, United States, 75231
    - GSK Investigational Site
  - Duncanville, Texas, United States, 75137
    - GSK Investigational Site
  - El Paso, Texas, United States, 79902
    - GSK Investigational Site
  - Fort Worth, Texas, United States, 76104
    - GSK Investigational Site
  - Houston, Texas, United States, 77030
    - GSK Investigational Site
  - Houston, Texas, United States, 77024
    - GSK Investigational Site
  - Round Rock, Texas, United States, 78681
    - GSK Investigational Site
  - San Antonio, Texas, United States, 78229
    - GSK Investigational Site
  - Tyler, Texas, United States, 75702
    - GSK Investigational Site
  - Waco, Texas, United States, 76712
    - GSK Investigational Site
- Utah
  - Ogden, Utah, United States, 84403
    - GSK Investigational Site
- Virginia
  - Chesapeake, Virginia, United States, 23320
    - GSK Investigational Site
  - Fairfax, Virginia, United States, 22031
    - GSK Investigational Site
  - Richland, Virginia, United States, 24641
    - GSK Investigational Site
- Washington
  - Kirkland, Washington, United States
    - GSK Investigational Site
  - Seattle, Washington, United States, 98104
    - GSK Investigational Site
  - Vancouver, Washington, United States, 98684
    - GSK Investigational Site
  - Yakima, Washington, United States, 98902
    - GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

Female

Description

Inclusion Criteria:

Have histologically or cytologically confirmed ErbB2-overexpressing invasive carcinoma (TX or T1-4) of the breast at the time of the initial diagnosis and have undergone adequate excision of tumor;
Had tumors that overexpress ErbB2 defined as 3+ by IHC or c-erbB2 gene amplification by FISH (ErbB2 expression/amplification must be documented prior to study entry; however, a tumor tissue sample must be sent to a central laboratory for subsequent re-analysis of ErbB2 status);
Have Stage I through Stage IIIc disease according to the American Joint Committee on Cancer (6th edition) staging criteria for breast cancer and meet one of the following criteria:

node-positive disease defined as: one positive lymph node by sentinel node biopsy OR at least 1 positive lymph node found among at least 6 axillary nodes examined on axillary node dissection OR status post axillary radiotherapy for sterilization if clinically evaluated as cN1 or cN2 (if sentinel node biopsy is positive, subject may either undergo an axillary node dissection or radiotherapy to the axilla).

node-positive disease evaluated as: ipsilateral axillary lymph nodes cN0-2 by clinical evaluation and axillary lymph nodes pNX, pN0(i+), or pN1-3 by pathological evaluation [patients with pN3 (Stage IIIc disease) must be disease free following completion of neoadjuvant or adjuvant chemotherapy for at least 12 months and must not have been lost to follow up].

OR node-negative disease defined as: negative sentinel node biopsy OR no positive lymph nodes found among at least 6 axillary nodes examined on axillary node dissection OR status post axillary radiotherapy for sterilization if clinically evaluated as cN0.

node-negative disease categorized as: high-risk disease (tumor >2.0 cm if ER and/or progesterone receptor (PgR) positive disease is present or tumor >1.0 cm if ER and PgR negative disease) OR intermediate-risk disease (tumor 1.0-2.0 cm and ER and/or PgR positive disease).

Women with synchronous bilateral invasive breast cancer or synchronous DCIS of either the contralateral or ipsilateral breast at the time of the initial diagnosis are also eligible;
Have undergone either mastectomy OR lumpectomy;
Have received and completed treatment with a neoadjuvant or adjuvant chemotherapy regimen containing either an anthracycline or a taxane; or any cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimen;
May continue to receive endocrine therapy while taking study medication, if endocrine therapy was initiated as either adjuvant therapy for treatment of the initial diagnosis of invasive breast cancer or for ovarian function suppression; however, endocrine therapy may not be initiated while taking study medication. Endocrine therapy agents may be switched while participating in this study (e.g., stop tamoxifen and start letrozole);
May have received prior radiotherapy as treatment for primary tumor; however, is not required for study entry;
May continue to receive radiotherapy while taking study medication, if radiotherapy was initiated as adjuvant therapy for treatment of the initial diagnosis of invasive breast cancer;
May continue to receive bisphosphonates only for treatment of documented osteoporosis, but not as treatment or prophylaxis of bone metastases;
All women eligible for adjuvant treatment with trastuzumab, including those diagnosed and treated within the last six months, must be considered for such treatment prior to being offered participation in this study. Participation in this study will be allowed only if the physician and patient have considered and discussed at length the advantages of trastuzumab, but have mutually decided against initiating trastuzumab therapy.
Have clinical and radiologic assessments that are negative for local or regional recurrence of disease or metastatic disease at the time of study entry;
if signs or symptoms suggestive of either recurrence of disease or metastatic disease are present, the appropriate radiological imaging must be performed
if the following laboratory results are present, the appropriate radiological imaging must be performed:
for AST/ALT ≥2×ULN or ALP ≥2×ULN (not in the bone fraction), an abdominal CT or MRI must be done
for ALP≥2×ULN in the bone fraction, a bone scan must be done; a confirmatory x-ray, CT scan or MRI scan or biopsy is required if the results of the bone scan are inconclusive
Have a unilateral/bilateral mammogram within 12 months prior to study entry;
Have an analysis of both ER and PgR on the primary tumor prior to study entry;
Have a cardiac ejection fraction within institutional range of normal as measured by either echocardiogram or multigated acquisition scans;
Have an Eastern Cooperative Oncology Group Performance Status of 0 to 1;
Women with a history of non-breast malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence. Women with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical carcinoma in situ, melanoma in situ, and basal cell or squamous cell carcinoma of the skin;
Are able to swallow and retain oral medication;
Have a paraffin-embedded tissue block from an archived tumor tissue from the primary tumor or twenty (20) slides of paraffin-embedded tissue available for biomarker analysis;
Have adequate organ function defined as: absolute neutrophil count ≥1.5× 10^9/L; hemoglobin ≥9 g/dL; platelets ≥75 × 10^9/L; albumin ≥2.5 g/dL; serum bilirubin ≤1.25 ×ULN; aspartate aminotransferase and alanine aminotransferase ≤3 × ULN and serum creatinine ≤2.0 mg/dL or calculated creatinine clearance ≥40 mL/min
Have signed the informed consent form (ICF);
Women of child-bearing potential must have a negative serum pregnancy test at screening and agree to complete abstinence from intercourse or consistent and correct use of an acceptable methods of birth control from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication:

Exclusion Criteria:

Have clinical and radiologic evidence of local or regional recurrence of disease or metastatic disease at the time of study entry;
Had metachronous invasive breast cancer (breast cancers diagnosed at different times);
Have a prior history of other breast cancer malignancies, including DCIS;
Are unable to provide archived tumor tissue samples for assay;
Had prior therapy with an ErbB1 and/or ErbB2 inhibitor; women who experienced a hypersensitivity or allergic reaction to trastuzumab during the first infusion and were unable to complete this infusion are eligible;
Receive concurrent anti-cancer therapy (chemotherapy, immunotherapy, and biologic therapy) while taking study medication;
Have unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;
Have malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Women with ulcerative colitis are also excluded;
Have a concurrent disease or condition that would make the woman inappropriate for study participation, or any serious medical disorder that would interfere with the woman's safety;
Have an active or uncontrolled infection;
Have dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;
Have a known history of uncontrolled or symptomatic angina, arrhythmias, or CHF;
Are pregnant or breastfeeding;
Receive concurrent treatment with an investigational agent; women, who are in follow-up in another clinical trial where the primary endpoint has been met and the interval between assessments is ≥12 months and radiological imaging is not required at these assessments, are eligible;
Receive concurrent treatment with a selected list of strong inducers and inhibitors of CYP3A4;
Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication;
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib or excipients;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Triple

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo 6 tablets daily for 12 months	Other: placebo 6 tablets daily for 12 months
Experimental: Lapatinib Lapatinib 1500 mg (6 tablets) daily for 12 months	Drug: lapatinib Lapatinib 1500 mg (6 tablets) daily for 12 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) Time Frame: From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])	DFS=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause. The date of the event is the earliest date of the occurrence of any of the following: local recurrence (LR) following mastectomy; LR in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer, including ductal carcinoma in situ; other second primary cancer (excluding squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, or lobular carcinoma in situ of the breast); death from any cause without a prior event. Par. who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored. Par. who did not withdraw from the study and did not experience a specified event or death were to be censored (follow-up ongoing) at the last visit date available at which progression was assessed.	From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])

Secondary Outcome Measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

P Goss, I Smith, J O'Shaughnessy, B Ejlertsen, M Kaufmann, F Boyle, A Buzdar, P Fumoleau, W Gradishar, M Martin, B Moy, M Piccart-Gebhart, K I Pritchard, D Lindquist, Y Chavarri-Guerra, G Aktan, E Rappold, L S Williams, D M Finkelstein. Resubmission: A Randomized Trial of Adjuvant Lapatinib in Women with Early Stage HER2 Overexpressing Breast Cancer. Lancet Oncol. 2012;S 1470-2045(12):70508-9.
Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.
Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol. 2014 Aug 1;32(22):2296-303. doi: 10.1200/JCO.2013.52.9867. Epub 2014 Mar 31.
Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM; TEACH investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Jan;14(1):88-96. doi: 10.1016/S1470-2045(12)70508-9. Epub 2012 Dec 10. Erratum In: Lancet Oncol. 2013 Feb;14(2):e47.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2006

Primary Completion (Actual)

September 1, 2011

Study Completion (Actual)

July 1, 2013

Study Registration Dates

First Submitted

September 7, 2006

First Submitted That Met QC Criteria

September 7, 2006

First Posted (Estimate)

September 11, 2006

Study Record Updates

Last Update Posted (Estimate)

August 18, 2014

Last Update Submitted That Met QC Criteria

August 14, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

EGF105485

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms, Breast

Emory University
Eisai Inc.

Terminated

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, Breast

United States
Seagen Inc.

Completed

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Triple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast Neoplasms

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene Corporation

Terminated

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer

United States
Innocrin Pharmaceutical

Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (CLARITY-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast

United States
G1 Therapeutics, Inc.

Terminated

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Breast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasms

United States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
Dana-Farber Cancer Institute
Conquer Cancer Foundation

Recruiting

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
GlaxoSmithKline

Completed

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Neoplasms, Breast

United States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Neoplasms, Breast

United States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
MedSIR
Hoffmann-La Roche

Completed

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (ATRACTIB)

Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer

Spain, France, United Kingdom, Germany, Italy

Clinical Trials on placebo

Galderma R&D

Completed

Effect of CD07805/47 Gel in Rosacea Flushing

Rosacea

Germany
SamA Pharmaceutical Co., Ltd

Unknown

Clinical Trials to Assess the Efficacy and Safety of HLIM

Acute Bronchitis | Acute Upper Respiratory Tract Infection

Korea, Republic of
National Institute on Drug Abuse (NIDA)

Completed

Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics

Cannabis Use

United States
AstraZeneca
Parexel; Spandauer Damm 130; 14050; Berlin, Germany

Completed

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Male Subjects With Type II Diabetes (T2DM)

Germany
Heptares Therapeutics Limited

Completed

Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects (HTL0018318)

Pharmacokinetics | Safety Issues

United Kingdom
GlaxoSmithKline

Completed

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing

Completed

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Parkinson Disease

China
Italfarmaco

Completed

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy

Becker Muscular Dystrophy

Netherlands, Italy
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
West Penn Allegheny Health System

Completed

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

Asthma | Allergic Rhinitis

United States

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Died (Overall Survival) Time Frame: From the date of randomization until death from any cause (assessed up to 6 years; 1 year of treatment and 5 years of follow-up [median of 5.3 years for final analysis])	Overall Survival (OS) is defined as the time from randomization until death from any cause. Data are presented as the number of participants who died. For participants who did not die, time to death was censored at the last date the participant was known to be alive.	From the date of randomization until death from any cause (assessed up to 6 years; 1 year of treatment and 5 years of follow-up [median of 5.3 years for final analysis])
Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) Time Frame: From the date of randomization until the date of the first occurrence of an objective disease recurrence or contralateral breast cancer (assessed up to 6 years; 1 year of treatment and 5.3 years of follow-up [median of 5 years for final analysis])	Recurrence is defined as experiencing a recurrence of initial disease or contralateral breast cancer after randomization. Time to first recurrence is defined as the interval between the date of randomization and the date of the first occurrence of an objective disease recurrence or contralateral breast cancer. Time to first recurrence included the first occurrence at one of the following sites as an event: local recurrence following mastectomy; local recurrence in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer, including ductal carcinoma in situ (DCIS).	From the date of randomization until the date of the first occurrence of an objective disease recurrence or contralateral breast cancer (assessed up to 6 years; 1 year of treatment and 5.3 years of follow-up [median of 5 years for final analysis])
Percentage of Participants With the Indicated Period of Distant Recurrence-free Survival (Time to Distant Recurrence) Time Frame: From the date of randomization until the date of the first occurrence of a distant recurrence (assessed up to 6 years; 1 year of treatment and 5 years of follow-up [median of 5.3 years for final analysis])	Distant recurrence (metastatic disease) is defined as a tumor in any area of the body not including those defined as local or regional recurrence. Sites of distant recurrence include: skin, subcutaneous tissue, and lymph nodes (excluding those described for local and regional recurrence); bone marrow; skeletal; lungs and pleural; ascites and pleural effusions; liver and other viscera; and central nervous system (CNS). Time to distant recurrence is defined as the interval between the date of randomization and the date of the first occurrence of a distant recurrence.	From the date of randomization until the date of the first occurrence of a distant recurrence (assessed up to 6 years; 1 year of treatment and 5 years of follow-up [median of 5.3 years for final analysis])
Time to Central Nervous System (CNS) Recurrence Time Frame: From the date of randomization until the date of the first occurrence of a CNS recurrence (assessed up to 6 years [1 year of treatment and 5 years of follow-up; median of 5.3 years for final analysis])	Time to CNS recurrence is defined as the interval between the date of randomization and the date of the occurrence of a CNS recurrence if noted as part of the participant's first recurrence. Time to CNS recurrence was not calculated; data are presented as the number of participants with CNS recurrence in the subsequent outcome measure table.	From the date of randomization until the date of the first occurrence of a CNS recurrence (assessed up to 6 years [1 year of treatment and 5 years of follow-up; median of 5.3 years for final analysis])
Number of Participants With CNS Recurrence Time Frame: From the date of randomization until the date of the first occurrence of a CNS recurrence (assessed up to 6 years [1 year of treatment and 5 years of follow-up; median of 5.3 years for final analysis])	The number of participants experiencing a CNS recurrence was summarized.	From the date of randomization until the date of the first occurrence of a CNS recurrence (assessed up to 6 years [1 year of treatment and 5 years of follow-up; median of 5.3 years for final analysis])
Modified Disease-free Survival (MDFS) Time Frame: From the date of randomization until the date of the first occurrence of an objective disease recurrence, contralateral breast cancer, or death from any cause (assessed up to 6 years)	Modified disease recurrence=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence, contralateral breast cancer, or death from any cause. The date of the event=the earliest date of the occurrence of any of the following events: local recurrence following mastectomy; local recurrence in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence; contralateral breast cancer, including DCIS; death from any cause without a prior event. MDFS was not calculated; data are presented as the number of participants with any recurrence of the initial disease, contralateral breast cancer, or death (disease-free survival) in the subsequent outcome measure table.	From the date of randomization until the date of the first occurrence of an objective disease recurrence, contralateral breast cancer, or death from any cause (assessed up to 6 years)
Number of Participants With Any Recurrence of the Initial Disease, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) Time Frame: From the date of randomization until the date of the first occurrence of an objective disease recurrence, contralateral breast cancer, or death from any cause (assessed up to 6 years)	DFS=interval between the date of randomization and the date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause. The date of the event is the earliest date of the occurrence of any of the following: local recurrence (LR) following mastectomy; LR in ipsilateral breast following lumpectomy; regional recurrence; distant recurrence and contralateral breast cancer, including ductal carcinoma in situ; or death from any cause without a prior event. Participants who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored. Participants who did not withdraw from the study and did not experience a specified event or death were to be censored (follow-up ongoing) at the last visit date available at which progression was assessed.	From the date of randomization until the date of the first occurrence of an objective disease recurrence, contralateral breast cancer, or death from any cause (assessed up to 6 years)
Change From Baseline in Short Form-36 Version 2 (SF-36 v2) Scores for the Physical Component Summary (PCS) Time Frame: Baseline, Month 6, Month 12, and every 6 months after discontinuation of study treatment for 24 months (up to a maximum of 3 study years)	The SF-36 v2 is a self-administered, health-related quality of life (QoL) metric. It is a 36-item questionnaire designed to measure 8 domains of functional health status and well-being: physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health. Each domain is scored from 0 (poorer health) to 100 (better health).The PCS score is a summary score representing overall physical health, which is derived from the 8 domain scores. As with each domain score, the PCS score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Missing post-Baseline data were imputed using the last observation carried forward (LOCF) method. The scores were analyzed using an analysis of covariance (ANCOVA) model, adjusting for Baseline sub-scale score, treatment, and country. Positive changes from Baseline indicate improvement.	Baseline, Month 6, Month 12, and every 6 months after discontinuation of study treatment for 24 months (up to a maximum of 3 study years)
Change From Baseline in SF-36 v2 Scores for the Mental Component Summary (MCS) Time Frame: Baseline, Month 6, Month 12, and every 6 months after discontinuation of study treatment for 24 months (up to a maximum of 3 study years)	The SF-36 v2 is a self-administered, health-related quality of life (QoL) metric. It is a 36-item questionnaire designed to measure 8 domains of functional health status and well-being: physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health. Each domain is scored from 0 (poorer health) to 100 (better health).The MCS score is a summary score representing overall mental health, which is derived from the 8 domain scores. As with each domain score, the MCS score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Missing post-Baseline data were imputed using the LOCF method. The scores were analyzed using an ANCOVA model adjusting for Baseline sub-scale score, treatment, and country. Positive changes from Baseline indicate improvement.	Baseline, Month 6, Month 12, and every 6 months after discontinuation of study treatment for 24 months (up to a maximum of 3 study years)
Change From Baseline in the SF-36 v2 Domain Scores for Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH) Time Frame: Baseline, Month 6, Month 12, and every 6 months after discontinuation of study treatment for 24 months (up to a maximum of 3 study years)	The SF-36 v2 is a self-administered, health-related quality of life (QoL) metric. It is a 36-item questionnaire designed to measure 8 domains of functional health status and well-being: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) perceptions, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH). Each domain is scored from 0 (poorer health) to 100 (better health); higher scores represent better health. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Missing post-Baseline data were imputed using the LOCF method. The scores were analyzed using an ANCOVA model, adjusting for Baseline sub-scale score, treatment, and country. Positive changes from Baseline indicate improvement.	Baseline, Month 6, Month 12, and every 6 months after discontinuation of study treatment for 24 months (up to a maximum of 3 study years)
Number of Participants With Hematology Values Outside the Reference Range for the Indicated Parameters Time Frame: At Baseline and every 3 months thereafter up to Month 12/Early Withdrawal Visit	The hematology parameters assessed were: basophils (Bs) in giga (10^9) per liter (GI/L) and in percentage (%), eosinophils (Eo) in GI/L and %, hematocrit, hemoglobin, lymphocytes (Lmph) in GI/L and %, monocytes (Mono) in GI/L and %, platelet count, Red Blood Cell (RBC) count, total neutrophil count (TNC) in GI/L and %, and White Blood Cell (WBC) count. The Baseline (BL) value is the last available pre-treatment result recorded. "Any post-Baseline value" was based on results recorded at any scheduled or unscheduled post-Baseline visits. The prevalence of values lying outside the reference (ref.) range (high or low) is presented for BL and "any post-Baseline" (APBL) visit. Two participants were randomized to placebo but received lapatinib; therefore, they are included in the lapatinib treatment arm. Data for the primary analysis (conducted in 2011) are reported.	At Baseline and every 3 months thereafter up to Month 12/Early Withdrawal Visit
Number of Participants With Clinical Chemistry Values Outside the Reference Range for the Indicated Parameters Time Frame: At Baseline and every 6 weeks thereafter up to Month 12/Early Withdrawal Visit	The clinical chemistry parameters assessed were: alanine amino transferase (ALT), albumin, alkaline phosphatase (ALP), aspartate amino transferase (AST), bicarbonate, blood urea nitrogen (BUN), bone alkaline phosphatase (Bone ALP), calcium, chloride, creatinine, creatinine clearance (Cr. Clearance), creatinine clearance estimated (Cr. Clrnc. est.), glucose, potassium, sodium, total bilirubin (Total Bln), total protein, urea, and uric acid. The Baseline (BL) value is the last available pre-treatment result recorded. "Any post-Baseline" value was based on results recorded at scheduled or unscheduled post-Baseline visits. The prevalence of values lying outside the reference (ref.) range (high or low) was presented for BL and "any post-Baseline" (APBL) visit. Two participants were randomized to placebo but received lapatinib; therefore, they are included in the lapatinib treatment arm.	At Baseline and every 6 weeks thereafter up to Month 12/Early Withdrawal Visit
Number of Participants With Non-laboratory Toxicities of the Indicated Toxicity Grades Time Frame: From the first dose of study treatment up to 12 months	Non-laboratory toxicities are defined as adverse events (AEs). The number of partcipants with any treatment-emergent AE of the indicated toxicity grade are summarized. Toxicity grading was according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 as follows: Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life threatening; Grade 5=death. The events that were not given a toxicity grade are categorized as "Not Applicable."	From the first dose of study treatment up to 12 months
Number of Participants Experiencing Primary or Secondary Cardiac Events Time Frame: From the date of randomization up to 12 months	A cardiac event is classified as a primary cardiac endpoint (PCE) or a secondary cardiac endpoint (SCE). PCE is defined as: cardiac death (cardiac death due to heart failure, myocardial infarction, or arrhythmia;or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event); severe symptomatic congestive heart failure (CHF) (as per New York Heart Association [NYHA] Class III or IV and an absolute decrease in left ventricular ejection fraction [LVEF] of more than 10 percentage points from Baseline and to a left ventricular ejection fraction [LVEF] value below 50%). SCE is defined as asymptomatic or mildly symptomatic cardiac events (NYHA Class I or II) and a significant decrease in LVEF, defined as an absolute decrease in LVEF of more than 10 percentage points from Baseline and to an LVEF value below 50%.	From the date of randomization up to 12 months
Number of Participants With the Indicated Electrocardiogram (ECG) Findings Time Frame: Screening and Month 12/Early Withdrawal Visit	12-lead ECG measurements were taken at Screening and at study conclusion/withdrawal. The number of participants with normal, abnormal clinically significant (CS), and abnormal not clinically significant (NCS) ECG findings, as classified by the investigator, were summarized. Participants with missing values were categorized as missing. Data for the primary analysis (conducted in 2011) are reported.	Screening and Month 12/Early Withdrawal Visit

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Publications and helpful links

General Publications

Study record dates

Study Major Dates

Study Start

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Estimate)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Neoplasms, Breast

Clinical Trials on placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations